**Supplemental Materials**

1. Adriaansen HJ, te Boekhorst PA, Hagemeijer AM, et al. Acute myeloid leukemia M4 with bone marrow eosinophilia (M4Eo) and inv(16)(p13q22) exhibits a specific immunophenotype with CD2 expression. *Blood* 1993; 81: 3043–3051.
2. Alessandri AJ, Reid GSD, Bader SA, et al. ETV6 (TEL)-AML1 pre-B acute lymphoblastic leukaemia cells are associated with a distinct antigen-presenting phenotype. *Br J Haematol* 2002; 116: 266–272.
3. Al-Mawali A, Gillis D, Hissaria P, et al. Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry. *Am J Clin Pathol* 2008; 129: 934–945.
4. Al-Mawali A, To LB, Gillis D, et al. The presence of leukaemia-associated phenotypes is an independent predictor of induction failure in acute myeloid leukaemia. *Int J Lab Hematol* 2009; 31: 61–68.
5. Al-Seraihy AS, Owaidah TM, Ayas M, et al. Clinical characteristics and outcome of children with biphenotypic acute leukemia. *Haematologica* 2009; 94: 1682–1690.
6. Attarbaschi A, Mann G, König M, et al. Mixed lineage leukemia-rearranged childhood pro-B and CD10-negative pre-B acute lymphoblastic leukemia constitute a distinct clinical entity. *Clin Cancer Res Off J Am Assoc Cancer Res* 2006; 12: 2988–2994.
7. Babusíková O, Zelezníková T, Kirschnerová G, et al. Hematogones in acute leukemia during and after therapy. *Leuk Lymphoma* 2008; 49: 1935–1944.
8. Baer MR, Stewart CC, Lawrence D, et al. Acute myeloid leukemia with 11q23 translocations: myelomonocytic immunophenotype by multiparameter flow cytometry. *Leukemia* 1998; 12: 317–325.
9. Basso G, Case C, Dell’Orto MC. Diagnosis and genetic subtypes of leukemia combining gene expression and flow cytometry. *Blood Cells Mol Dis* 2007; 39: 164–168.
10. Betz SA, Foucar K, Head DR, et al. False-positive flow cytometric platelet glycoprotein IIb/IIIa expression in myeloid leukemias secondary to platelet adherence to blasts. *Blood* 1992; 79: 2399–2403.
11. Biondi A, Luciano A, Bassan R, et al. CD2 expression in acute promyelocytic leukemia is associated with microgranular morphology (FAB M3v) but not with any PML gene breakpoint. *Leukemia* 1995; 9: 1461–1466.
12. Borkhardt A, Wuchter C, Viehmann S, et al. Infant acute lymphoblastic leukemia - combined cytogenetic, immunophenotypical and molecular analysis of 77 cases. *Leukemia* 2002; 16: 1685–1690.
13. Borowitz MJ, Shuster J, Carroll AJ, et al. Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group Study. *Blood* 1997; 89: 3960–3966.
14. Borowitz MJ, Guenther KL, Shults KE, et al. Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. *Am J Clin Pathol* 1993; 100: 534–540.
15. Buldini B, Zangrando A, Michielotto B, et al. Identification of immunophenotypic signatures by clustering analysis in pediatric patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. *Am J Hematol* 2010; 85: 138–141.
16. Cesana C, Klersy C, Scarpati B, et al. Flow cytometry vs cytomorphology for the detection of hematologic malignancy in body cavity fluids. *Leuk Res* 2010; 34: 1027–1034.
17. Cesana C, Klersy C, Scarpati B, et al. Flow cytometry and cytomorphology evaluation of hematologic malignancy in cerebrospinal fluids: comparison with retrospective clinical outcome. *Ann Hematol* 2011; 90: 827–835.
18. Chen W, Karandikar NJ, McKenna RW, et al. Stability of leukemia-associated immunophenotypes in precursor B-lymphoblastic leukemia/lymphoma: a single institution experience. *Am J Clin Pathol* 2007; 127: 39–46.
19. Ciudad J, San Miguel JF, López-Berges MC, et al. Detection of abnormalities in B-cell differentiation pattern is a useful tool to predict relapse in precursor-B-ALL. *Br J Haematol* 1999; 104: 695–705.
20. Claxton DF, Reading CL, Nagarajan L, et al. Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukemia. *Blood* 1992; 80: 582–586.
21. Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. *Lancet Oncol* 2009; 10: 147–156.
22. Craig FE, Ohori NP, Gorrill TS, et al. Flow cytometric immunophenotyping of cerebrospinal fluid specimens. *Am J Clin Pathol* 2011; 135: 22–34.
23. Czuczman MS, Dodge RK, Stewart CC, et al. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. *Blood* 1999; 93: 3931–3939.
24. Dakka N, Bellaoui H, Khattab M, et al. Immunologic profile and outcome of childhood acute lymphoblastic leukemia (ALL) in Morocco. *J Pediatr Hematol Oncol* 2007; 29: 574–580.
25. Dalmazzo LFF, Jácomo RH, Marinato AF, et al. The presence of CD56/CD16 in T-cell acute lymphoblastic leukaemia correlates with the expression of cytotoxic molecules and is associated with worse response to treatment. *Br J Haematol* 2009; 144: 223–229.
26. D’Arena G, Cascavilla N, Nunziata G, et al. Usefulness of RA and RO isoforms of common leukocyte antigen (CD45) for early distinction between normal and abnormal promyelocytes. *Leuk Lymphom*a 2002; 43: 1823–1825.
27. De Zen L, Bicciato S, te Kronnie G, et al. Computational analysis of flow-cytometry antigen expression profiles in childhood acute lymphoblastic leukemia: an MLL/AF4 identification. *Leukemia* 2003; 17: 1557–1565.
28. De J, Zanjani R, Hibbard M, et al. Immunophenotypic profile predictive of KIT activating mutations in AML1-ETO leukemia. *Am J Clin Pathol* 2007; 128: 550–557.
29. Del Vecchio L, Brando B, Lanza F, et al. Recommended reporting format for flow cytometry diagnosis of acute leukemia. *Haematologica* 2004; 89: 594–598.
30. Derolf AR, Björklund E, Mazur J, et al. Expression patterns of CD33 and CD15 predict outcome in patients with acute myeloid leukemia. *Leuk Lymphoma* 2008; 49: 1279–1291.
31. Dimov ND, Medeiros LJ, Ravandi F, et al. Acute promyelocytic leukemia at time of relapse commonly demonstrates cytogenetic evidence of clonal evolution and variability in blast immunophenotypic features. *Am J Clin Pathol* 2010; 133: 484–490.
32. Djokic M, Björklund E, Blennow E, et al. Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia. *Haematologica* 2009; 94: 1016–1019.
33. Dong HY, Kung JX, Bhardwaj V, et al. Flow cytometry rapidly identifies all acute promyelocytic leukemias with high specificity independent of underlying cytogenetic abnormalities. *Am J Clin Pathol* 2011; 135: 76–84.
34. Donskoy E, Tausche F, Altman A, et al. Association of immunophenotype with cerebrospinal fluid involvement in childhood B-lineage acute lymphoblastic leukemia. *Am J Clin Pathol* 1997; 107: 608–616.
35. Dunphy CH. Comprehensive review of adult acute myelogenous leukemia: cytomorphological, enzyme cytochemical, flow cytometric immunophenotypic, and cytogenetic findings. *J Clin Lab Anal* 1999; 13: 19–26.
36. Dunphy CH, Chu JY. Aberrant CD2 expression in precursor-B acute lymphoblastic leukemia of childhood. *Am J Hematol* 1996; 52: 224–226.
37. Edwards RH, Wasik MA, Finan J, et al. Evidence for early hematopoietic progenitor cell involvement in acute promyelocytic leukemia. *Am J Clin Pathol* 1999; 112: 819–827.
38. Elgendi HM, Mekawy MA, Abdel Wahab SE-A, et al. AC133 expression in egyptian children with acute leukemia: impact on treatment response and disease outcome. *J Pediatr Hematol Oncol* 2010; 32: 286–293.
39. Eto T, Akashi K, Harada M, et al. Biological characteristics of CD7 positive acute myelogenous leukaemia. *Br J Haematol* 1992; 82: 508–514.
40. Faber J, Kantarjian H, Roberts MW, et al. Terminal deoxynucleotidyl transferase-negative acute lymphoblastic leukemia. *Arch Pathol Lab Med* 2000; 124: 92–97.
41. Farahat N, Lens D, Morilla R, et al. Differential TdT expression in acute leukemia by flow cytometry: a quantitative study. *Leukemia* 1995; 9: 583–587.
42. Fleming DR, Doukas MA, Jennings DC, et al. Diagnostic and clinical implications of lineage fidelity in acute leukemia patients undergoing allogeneic stem cell transplantation. *Leuk Lymphoma* 2000; 36: 309–313.
43. Fukushima T, Sumazaki R, Koike K, et al. Multicolor flow-cytometric, morphologic, and clonogenic analysis of marrow CD10-positive cells in children with leukemia in remission or nonmalignant diseases. *J Pediatr Hematol Oncol* 1998; 20: 222–228.
44. García Vela JA, Monteserin MC, Delgado I, et al. Aberrant immunophenotypes detected by flow cytometry in acute lymphoblastic leukemia. *Leuk Lymphoma* 2000; 36: 275–284.
45. Garnache-Ottou F, Feuillard J, Ferrand C, et al. Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. *Br J Haematol* 2009; 145: 624–636.
46. Gerr H, Zimmermann M, Schrappe M, et al. Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations. *Br J Haematol* 2010; 149: 84–92.
47. Gudowius S, Recker K, Laws H-J, et al. Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL. *Klin Padiatr* 2006; 218: 327–333.
48. Hans CP, Finn WG, Singleton TP, et al. Usefulness of anti-CD117 in the flow cytometric analysis of acute leukemia. *Am J Clin Pathol* 2002; 117: 301–305.
49. Haycocks NG, Lawrence L, Cain JW, et al. Optimizing antibody panels for efficient and cost-effective flow cytometric diagnosis of acute leukemia. *Cytometry B Clin Cytom* 2011; 80: 221–229.
50. Helleberg C, Knudsen H, Hansen PB, et al. CD34+ megakaryoblastic leukaemic cells are CD38-, but CD61+ and glycophorin A+: improved criteria for diagnosis of AML-M7? *Leukemia* 1997; 11: 830–834.
51. Hoehn D, Medeiros LJ, Chen SS, et al. CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia. *Am J Clin Pathol* 2012; 137: 213–219.
52. Hurwitz CA, Raimondi SC, Head D, et al. Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. *Blood* 1992; 80: 3182–3188.
53. Imamura N, Kajihara H, Kuramoto A. Flow cytometric analysis of peroxidase negative acute leukemias by monoclonal antibodies--II. Acute megakaryoblastic and acute pro-megakaryocytic leukemias. *Leuk Res* 1988; 12: 279–289.
54. Kaleem Z, White G. Diagnostic criteria for minimally differentiated acute myeloid leukemia (AML-M0). Evaluation and a proposal. *Am J Clin Pathol* 2001; 115: 876–884.
55. Kaleem Z, Crawford E, Pathan MH, et al. Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data. *Arch Pathol Lab Med* 2003; 127: 42–48.
56. Kalina T, Vaskova M, Mejstrikova E, et al. Myeloid antigens in childhood lymphoblastic leukemia: clinical data point to regulation of CD66c distinct from other myeloid antigens. *BMC Cancer* 2005; 5: 38.
57. Kern W, Haferlach C, Bacher U, et al. Flow cytometric identification of acute myeloid leukemia with limited differentiation and NPM1 type A mutation: a new biologically defined entity. *Leukemia* 2009; 23: 1361–1364.
58. Kern W, Voskova D, Schoch C, et al. Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia. *Haematologica* 2004; 89: 528–540.
59. Kern W, Bacher U, Haferlach C, et al. Acute monoblastic/monocytic leukemia and chronic myelomonocytic leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cells. *Leuk Lymphoma* 2011; 52: 92–100.
60. Khalidi HS, Chang KL, Medeiros LJ, et al. Acute lymphoblastic leukemia. Survey of immunophenotype, French-American-British classification, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases. *Am J Clin Pathol* 1999; 111: 467–476.
61. Khalidi HS, Medeiros LJ, Chang KL, et al. The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities. *Am J Clin Pathol* 1998; 109: 211–220.
62. Khoury H, Dalal BI, Nevill TJ, et al. Acute myelogenous leukemia with t(8;21)--identification of a specific immunophenotype. *Leuk Lymphoma* 2003; 44: 1713–1718.
63. Khoury H, Dalal BI, Nantel SH, et al. Correlation between karyotype and quantitative immunophenotype in acute myelogenous leukemia with t(8;21). *Mod Pathol* 2004; 17: 1211–1216.
64. Kotylo PK, Seo IS, Smith FO, et al. Flow cytometric immunophenotypic characterization of pediatric and adult minimally differentiated acute myeloid leukemia (AML-M0). *Am J Clin Pathol* 2000; 113: 193–200.
65. Krasinskas AM, Wasik MA, Kamoun M, et al. The usefulness of CD64, other monocyte-associated antigens, and CD45 gating in the subclassification of acute myeloid leukemias with monocytic differentiation. *Am J Clin Pathol* 1998; 110: 797–805.
66. Langebrake C, Creutzig U, Reinhardt D. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. *Klin Padiatr* 2005; 217: 126–134.
67. Lanza F, Rigolin GM, Moretti S, et al. Prognostic value of immunophenotypic characteristics of blast cells in acute myeloid leukemia. *Leuk Lymphoma* 1994;13 Suppl 1: 81–85.
68. Launder TM, Bray RA, Stempora L, et al. Lymphoid-associated antigen expression by acute myeloid leukemia. *Am J Clin Pathol* 1996; 106: 185–191.
69. Lewis RE, Cruse JM, Sanders CM, et al. The immunophenotype of pre-TALL/LBL revisited. *Exp Mol Pathol* 2006; 81: 162–165.
70. Lewis RE, Cruse JM, Webb RN, et al. Contrasting antigenic maturation patterns in M0-M2 versus M3 acute myeloid leukemias. *Exp Mol Pathol* 2007; 83: 269–273.
71. Li X, Du W, Liu W, Li X, et al. Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse. *Acta Pathol Microbiol Immunol Scand* 2010; 118: 353–359.
72. Lin P, Hao S, Medeiros LJ, et al. Expression of CD2 in acute promyelocytic leukemia correlates with short form of PML-RARalpha transcripts and poorer prognosis. *Am J Clin Pathol* 2004; 121: 402–407.
73. Liu L, McGavran L, Lovell MA, et al. Non positive terminal deoxynucleotidyl transferase in pediatric precursor B-lymphoblastic leukemia. *Am J Clin Pathol* 2004; 121: 810–815.
74. Loken MR, Wells DA. The role of flow cytometry in myelodysplastic syndromes. *J Natl Compr Cancer Netw* 2008; 6: 935–941.
75. Manera R, Ramirez I, Mullins J, et al. Pilot studies of species-specific chemotherapy of childhood acute lymphoblastic leukemia using genotype and immunophenotype. *Leukemia* 2000; 14: 1354–1361.
76. Mann KP, DeCastro CM, Liu J, et al. Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes. *Am J Clin Pathol* 1997; 107: 653–660.
77. Matutes E, Pickl WF, Van’t Veer M, et al. Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. *Blood* 2011; 117: 3163–3171.
78. Medeiros BC, Kohrt HE, Arber DA, et al. Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2). *Leuk Res* 2010; 34: 594–597.
79. Mejstrikova E, Volejnikova J, Fronkova E, et al. Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria. *Haematologica* 2010; 95: 928–935.
80. Nikolova M, Guenova M, Taskov H, et al. Levels of expression of CAF7 (CD98) have prognostic significance in adult acute leukemia. *Leuk Res* 1998; 22: 39–47.
81. Nomdedeu J, Bussaglia E, Villamor N, et al. Immunophenotype of acute myeloid leukemia with NPM mutations: prognostic impact of the leukemic compartment size. *Leuk Res* 2011; 35: 163–168.
82. Oelschlaegel U, Mohr B, Schaich M, et al. HLA-DRneg patients without acute promyelocytic leukemia show distinct immunophenotypic, genetic, molecular, and cytomorphologic characteristics compared to acute promyelocytic leukemia. *Cytometry B Clin Cytom* 2009; 76: 321–327.
83. Orfao A, Chillón MC, Bortoluci AM, et al. The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARalpha gene rearrangements. *Haematologica* 1999; 84: 405–412.
84. Paietta E, Racevskis J, Neuberg D, et al. Expression of CD25 (interleukin-2 receptor alpha chain) in adult acute lymphoblastic leukemia predicts for the presence of BCR/ABL fusion transcripts: results of a preliminary laboratory analysis of ECOG/MRC Intergroup Study E2993. Eastern Cooperative Oncology Group/Medical Research Council. *Leukemia* 1997; 11: 1887–1890.
85. Paietta E, Goloubeva O, Neuberg D, et al. A surrogate marker profile for PML/RAR alpha expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes. *Cytometry B Clin Cytom* 2004; 59: 1–9.
86. Peters JM, Ansari MQ. Multiparameter flow cytometry in the diagnosis and management of acute leukemia. *Arch Pathol Lab Med* 2011; 135: 44–54.
87. Porwit-MacDonald A, Janossy G, Ivory K, et al. Leukemia-associated changes identified by quantitative flow cytometry. IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8;21). *Blood* 1996; 87: 1162–1169.
88. Qadir M, Barcos M, Stewart CC, et al. Routine immunophenotyping in acute leukemia: Role in lineage assignment and reassignment. *Cytometry B Clin Cytom* 2006; 70: 329–334.
89. Ratei R, Sperling C, Karawajew L, et al. Immunophenotype and clinical characteristics of CD45-negative and CD45-positive childhood acute lymphoblastic leukemia. *Ann Hematol* 1998; 77: 107–114.
90. Reading CL, Estey EH, Huh YO, et al. Expression of unusual immunophenotype combinations in acute myelogenous leukemia. *Blood* 1993; 81: 3083–3090.
91. Schwartz S, Heinecke A, Zimmermann M, et al. Expression of the C-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance. *Leuk Lymphoma* 1999; 34: 85–94.
92. Scott AA, Head DR, Kopecky KJ, et al. HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3. *Blood* 1994; 84: 244–255.
93. Terstappen LW, Safford M, Unterhalt M, et al. Flow cytometric characterization of acute myeloid leukemia: IV. Comparison to the differentiation pathway of normal hematopoietic progenitor cells. *Leukemia* 1992; 6: 993–1000.
94. Terwijn M, Feller N, van Rhenen A, et al. Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML. *Eur J Cancer Oxf Engl* 1990 2009; 45: 1692–1699.
95. Tong H, Lu C, Zhang J, et al. Immunophenotypic, cytogenetic and clinical features of 192 AML patients in China. *Clin Exp Med* 2009; 9: 149–155.
96. Tong H, Wang Q, Lu C, et al. Immunophenotypic, cytogenetic, and clinical features of 207 cases of childhood acute lymphoblastic leukemia in china. *J Pediatr Hematol Oncol* 2011; 33: 437–441.
97. Tsagarakis NJ, Kentrou NA, Papadimitriou KA, et al. Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group. *Leuk Res* 2010; 34: 438–446.
98. Tucker J, Dorey E, Gregory WM, et al. Immunophenotype of blast cells in acute myeloid leukemia may be a useful predictive factor for outcome. *Hematol Oncol* 1990; 8: 47–58.
99. Unal S, Cetin M, Tuncer AM, et al. The prognostic impact of myeloid antigen expression in pediatric acute lymphoblastic leukemia patients. *Turk J Pediatr* 2008; 50: 533–536.
100. van Luijn MM, Westers TM, Chamuleau MED, et al. Class II-associated invariant chain peptide expression represents a novel parameter for flow cytometric detection of acute promyelocytic leukemia. *Am J Pathol* 2011; 179: 2157–2161.
101. Vargas SO, Hasegawa SL, Dorfman DM. Hematogones as an internal control in flow cytometric analysis of suspected acute lymphoblastic leukemia. *Pediat Develop Pathol* 1999; 2: 371–376.
102. Varma N, Agarwal C, Varma S. Evaluation of PML immunofluorescence, flow cytometric immunophenotypic analysis, and reverse transcriptase polymerase chain reaction for PML/RARa for rapid diagnosis of acute promyelocytic leukemia. *Cancer* 2011; 117: 435-436.
103. Vaskova M, Mejstrikova E, Kalina T, et al. Transfer of genomics information to flow cytometry: expression of CD27 and CD44 discriminates subtypes of acute lymphoblastic leukemia. *Leukemia* 2005; 19: 876–878.
104. Weir EG, Cowan K, LeBeau P, et al. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection. *Leukemia* 1999; 13: 558–567.
105. Wells SJ, Bray RA, Stempora LL, et al. CD117/CD34 expression in leukemic blasts. *Am J Clin Pathol* 1996; 106: 192–195.
106. Witte K-E, Ahlers J, Schäfer I, et al. High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia. *Pediatr Hematol Oncol* 2011; 28: 91–99.
107. Wuchter C, Harbott J, Schoch C, et al. Detection of acute leukemia cells with mixed lineage leukemia (MLL) gene rearrangements by flow cytometry using monoclonal antibody 7.1. *Leukemia* 2000; 14: 1232–1238.
108. Wuchter C, Ratei R, Spahn G, et al. Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping. *Haematologica* 2001; 86: 154–161.
109. Yang DT, Greenwood JH, Hartung L, et al. Flow cytometric analysis of different CD14 epitopes can help identify immature monocytic populations. *Am J Clin Pathol* 2005; 124: 930–936.
110. Ahmad EI, Akl HK, Hashem ME, et al. The biological characteristics of adult CD34+ acute promyelocytic leukemia. *Med Oncol* 2012; 29: 1119–1126.
111. Alapat D, Coviello-Malle J, Owens R, et al. Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma. *Am J Clin Pathol* 2012; 137: 93–100.
112. Alves GV de A, Fernandes ALA da C, Freire JM, et al. Flow cytometry immunophenotyping evaluation in acute lymphoblastic leukemia: correlation to factors affecting clinic outcome. *J Clin Lab Anal* 2012; 26: 431–440.
113. Angelot-Delettre F, Biichle S, Ferrand C, et al. Intracytoplasmic detection of TCL1--but not ILT7-by flow cytometry is useful for blastic plasmacytoid dendritic cell leukemia diagnosis. *Cytometry Part A* 2012; 81A: 718–724.
114. Atfy M, Eissa M, Salah HE, et al. Role of urokinase plasminogen activator receptor (CD87) as a prognostic marker in acute myeloid leukemia. *Med Oncol* 2012; 29: 2063–2069.
115. Belurkar S, Mantravadi H, Manohar C, et al. Correlation of morphologic and cytochemical diagnosis with flowcytometric analysis in acute leukemia. *J Cancer Res Ther* 2013; 9: 71–79.
116. Ben Salah N, Gouider E, Aounallah Skhiri H, et al. Immunophenotyping in adult acute myeloid leukemia: which prognostic value? *Tunis Med* 2012; 90: 602–605.
117. Béné MC, Porwit A. Acute leukemias of ambiguous lineage. *Semin Diagn Pathol 2012*; 29: 12–18.
118. Cario G, Rhein P, Mitlöhner R, et al. High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. *Haematologica* 2014; 99: 103–110.
119. Craddock KJ, Chen Y, Brandwein JM, et al. CD13 expression is an independent adverse prognostic factor in adults with Philadelphia chromosome negative B cell acute lymphoblastic leukemia. *Leuk Res* 2013; 37: 759–764.
120. Craig FE, Monaghan SA, Su*rti U,* et al. ZAP-70 and Bcl-2 expression in B lymphoblastic leukemia cells and hematogones*. Cytometry B Clin Cytom* 2012; 82: 85–92.
121. Dalal BI, Mansoor S, Manna M, et al. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia. *Clin Lymphoma Myeloma Leuk* 2012; 12: 274–279.
122. Ferrari A, Bussaglia E, Úbeda J, et al. Immunophenotype distinction between acute promyelocytic leukaemia and CD15- CD34- HLA-DR- acute myeloid leukaemia with nucleophosmin mutations. *Hematol Oncol* 2012; 30: 109–114.
123. Gorczyca W. Acute promyelocytic leukemia: four distinct patterns by flow cytometry immunophenotyping. *Pol J Pathol* 2012; 63: 8–17.
124. Hoffmann MH, Klausen TW, Boegsted M, et al. Clinical impact of leukemic blast heterogeneity at diagnosis in cytogenetic intermediate-risk acute myeloid leukemia. *Cytometry B Clin Cytom* 2012; 82: 123–131.
125. Hwang K, Park C-J, Jang S, et al. Flow cytometric quantification and immunophenotyping of leukemic stem cells in acute myeloid leukemia. *Ann Hematol* 2012; 91: 1541–1546.
126. Jiang G, Zhang M, Yue B, et al. PTK7: a new biomarker for immunophenotypic characterization of maturing T cells and T cell acute lymphoblastic leukemia. *Leuk Res* 2012; 36: 1347–1353.
127. Kamazani FM, Bahoush GR, Aghaeipour M, et al. CD44 and CD27 expression pattern in B cell precursor acute lymphoblastic leukemia and its clinical significance. *Med Oncol* 2013; 30: 359.
128. Larsen HØ, Roug AS, Just T, et al. Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up. Cytometry B Clin Cytom. 2012; 82:3–8.
129. Mirabelli P, Scalia G, Pascariello C, et al. ImageStream promyelocytic leukemia protein immunolocalization: in search of promyelocytic leukemia cells. *Cytometry Part A* 2012; 81A: 232–237.
130. McGregor S, McNeer J, Gurbuxani S. Beyond the 2008 World Health Organization classification: the role of the hematopathology laboratory in the diagnosis and management of acute lymphoblastic leukemia. *Semin Diagn Pathol* 2012; 29: 2–11.
131. Liu Y-R, Zhu H-H, Ruan G-R, et al. NPM1-mutated acute myeloid leukemia of monocytic or myeloid origin exhibit distinct immunophenotypes. *Leuk Res* 2013; 37: 737–741.
132. Patel JL, Smith LM, Anderson J, et al. The immunophenotype of T-lymphoblastic lymphoma in children and adolescents: a Children’s Oncology Group report. *Br J Haematol* 2012; 159: 454–461.
133. Ratei R, Schabath R, Karawajew L, et al. Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial. *Klin Padiatr* 2013; 225 Suppl 1: S34-39.
134. Wu C-P, Qing X, Wu C-Y, et al. Immunophenotype and increased presence of CD4(+)CD25(+) regulatory T cells in patients with acute lymphoblastic leukemia. *Oncol Lett* 2012; 3: 421–424.
135. Zheng W, Medeiros LJ, Young KH, et al. CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis. *Leuk Lymphoma* 2014; 55: 624–627.
136. Aziz SA, Sharma SK, Sabah I, et al. Prognostic significance of cell surface phenotype in acute lymphoblastic leukemia. *South Asian J Cancer* 2015; 4: 91–94.
137. Chopra A, Bakhshi S, Pramanik SK, et al. Immunophenotypic analysis of T-acute lymphoblastic leukemia. A CD5-based ETP-ALL perspective of non-ETP T-ALL. *Eur J Haematol* 2014; 92: 211–218.
138. Dalal BI, Al Mugairi A, Pi S, et al. Aberrant expression of CD13 identifies a subgroup of standard-risk adult acute lymphoblastic leukemia with inferior survival. *Clin Lymphoma Myeloma Leuk* 2014; 14: 239–244.
139. Cézar RS, Cerqueira BAV, da Paz S de S, et al. Outcome of B-Cell Acute Lymphoblastic Leukemia in Brazilian Children: Immunophenotypical, Hematological, and Clinical Evaluation. *J Pediatr Hematol Oncol* 2015; 37: 423–428.
140. Ahmadi A, Poorfathollah AA, Aghaiipour M, et al. Diagnostic value of CD117 in differential diagnosis of acute leukemias. *Tumour Biol* 2014; 35: 6763–6768.
141. Abdulateef NAB, Ismail MM, Aljedani H. Clinical significance of co-expression of aberrant antigens in acute leukemia: a retrospective cohort study in Makah Al Mukaramah, Saudi Arabia. *Asian Pac J Cancer Prev* 2014; 15: 221–227.
142. Franca R, Rebora P, Athanasakis E, et al. TNF-α SNP rs1800629 and risk of relapse in childhood acute lymphoblastic leukemia: relation to immunophenotype. *Pharmacogenomics* 2014; 15: 619–627.
143. Kamazani FM, Bahoush-Mehdiabadi G, Aghaeipour M, et al. The Expression and Prognostic Impact of CD95 Death Receptor and CD20, CD34 and CD44 Differentiation Markers in Pediatric Acute Lymphoblastic Leukemia. *Iran J Pediatr* 2014; 24: 371–380.
144. Dayama A, Dass J, Mishra P, et al. CSF Flow Cytometry for Detection of CNS Disease in Acute Lymphoblastic Leukemia Patients at Diagnosi. *Indian J Hematol Blood Transfus* 2013: 297–298.
145. Gupta A, Goyal M, Nidamanuri KR, et al. Your dilemma, my identity: unusual immunogenetic profiles of pediatric B cell acute lymphoblastic leukemia. *Indian J Pathol Microbiol* 2014; 57: 78–80.
146. Hagag AA, Nosair NA. Prognostic Impact of Neuropilin-1 Expression in Egyptian Children with B-lineage Acute Lymphoblastic Leukemia. *Mediterr J Hematol Infect Dis* 2015; 7: e2015009.
147. Hagag AA, Nosair NA, Ghaith FM, et al. Prognostic value of protease activated receptor-1 in children with acute lymphoblastic leukemia. *Mediterr J Hematol Infect Dis* 2014; 6: e2014029.
148. Hagag AA, Saad MA, Mohamed SA. Clinical significance of thymidine kinase in Egyptian children with acute lymphoblastic leukemia. *South Asian J Cancer* 2015; 4: 72–74.
149. Kelleher N, Gallardo D, González-Campos J, et al. Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy. *Leuk Lymphoma* 2016; 57: 86–91.
150. Kobayashi R, Takimoto T, Nakazawa A, et al. Inferior outcomes of stage III T lymphoblastic lymphoma relative to stage IV lymphoma and T-acute lymphoblastic leukemia: long-term comparison of outcomes in the JACLS NHL T-98 and ALL T-97 protocols. *Int J Hematol* 2014; 99: 743–749.
151. Kanderova V, Kuzilkova D, Stuchly J, et al. High-resolution Antibody Array Analysis of Childhood Acute Leukemia Cells. *Mol Cell Proteomics* 2016; 15: 1246-1261.
152. Lahjouji A, Bachir F, Bennani S, et al. The immunophenotype of adult T acute lymphoblastic leukemia in Morocco. *Exp Oncol* 2015; 37: 64–69.
153. Liu GJ, Cimmino L, Jude JG, et al. Pax5 loss imposes a reversible differentiation block in B-progenitor acute lymphoblastic leukemia. *Genes Dev* 2014; 28: 1337–1350.
154. Lu J, Ashwani N, Zhang M, et al. Children Diagnosed as Mixed-Phenotype Acute Leukemia Didn’t Benefit from the CCLG-2008 Protocol, Retrospective Analysis from Single Center. *Indian J Hematol Blood Transfus* 2015; 31: 32–37.
155. Martín-Martín L, López A, Vidriales B, et al. Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile. *Oncotarget* 2015; 6: 19204–19216.
156. Meyerson HJ, Osei E, Schweitzer K, et al. CD177 expression on neutrophils: in search of a clonal assay for myeloid neoplasia by flow cytometry. *Am J Clin Pathol* 2013; 140: 658–669.
157. Popov A, Verzhbitskaya T, Tsaur G, et al. Tumor cells detection in cerebrospinal fluid of children with acute leukemias by flow cytometry. *Pediatr Blood Cancer* 2013: 64–65.
158. Martínez-Laperche C, Gómez-García AM, Lassaletta Á, et al. Detection of occult cerebrospinal fluid involvement during maintenance therapy identifies a group of children with acute lymphoblastic leukemia at high risk for relapse. *Am J Hematol* 2013; 88: 359-364.
159. Ranta S, Nilsson F, Harila-Saari A, et al. Detection of central nervous system involvement in childhood acute lymphoblastic leukemia by cytomorphology and flow cytometry of the cerebrospinal fluid. *Pediatr Blood Cancer* 2015; 62: 951–956.
160. Sharma RK, Purohit A, Somasundaram V, et al. Aberrant myeloid antigen co-expression is correlated with high percentages of CD34-positive cells among blasts of acute lymphoblastic leukemia patients: an Indian tertiary care center perspective. *Blood Res* 2014; 49: 241–245.
161. Sukumaran R, Nair RA, Jacob PM, Nair Anila KAR, Prem S, Binitha R, Kusumakumary P. Flow cytometric analysis of Mixed phenotype acute leukemia: experience from a tertiary oncology center. *Indian J Pathol Microbiol* 2015; 58: 181–186.
162. Metrock LK, Summers RJ, Park S, et al. Utility of peripheral blood immunophenotyping by flow cytometry in the diagnosis of pediatric acute leukemia. *Pediatr Blood Cancer* 2017; 64: 1-6.
163. Weinberg OK, Seetharam M, Ren L, et al. Mixed phenotype acute leukemia: A study of 61 cases using World Health Organization and European Group for the Immunological Classification of Leukaemias criteria. *Am J Clin Pathol* 2014; 142: 803–808.
164. Broome HE1, Rassenti LZ, Wang HY, et al. ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia. *Leuk Res* 2011; 35: 1390-1394.
165. Baumgarth N, Roederer M. A practical approach to multicolor flow cytometry for immunophenotyping. *J Immunol Methods* 2000; 243: 77–97.
166. Brooimans RA, Kraan J, van Putten W, et al. Flow cytometric differential of leukocyte populations in normal bone marrow: influence of peripheral blood contamination. *Cytometry B Clin Cytom* 2009; 76: 18–26.
167. Cualing H, Kothari R, Balachander T. Immunophenotypic diagnosis of acute leukemia by using decision tree induction. *Lab Investig* 1999; 79: 205–212.
168. Drach D, Drach J, Glassl H, et al. Flow cytometric detection of cytoplasmic antigens in acute leukemias: implications for lineage assignment. *Leuk Res* 1993; 17: 455–461.
169. Finn WG, Carter KM, Raich R, et al Analysis of clinical flow cytometric immunophenotyping data by clustering on statistical manifolds: treating flow cytometry data as high-dimensional objects. *Cytometry B Clin Cytom* 2009; 76: 1–7.
170. Gorczyca W. Flow cytometry immunophenotypic characteristics of monocytic population in acute monocytic leukemia (AML-M5), acute myelomonocytic leukemia (AML-M4), and chronic myelomonocytic leukemia (CMML). *Methods Cell Biol* 2004; 75: 665–677.
171. Gratama JW, Bolhuis RL, Van ’t Veer MB. Quality control of flow cytometric immunophenotyping of haematological malignancies. *Clin Lab Haematol* 1999; 21: 155–160.
172. Harada N, Okamura S, Kubota A, et al. Analysis of acute myeloid leukemia cells by flow cytometry, introducing a new light-scattering classification. *J Cancer Res Clin Oncol* 1994; 120: 553–557.
173. Henderson LO, Marti GE, Gaigalas A, et al. Terminology and nomenclature for standardization in quantitative fluorescence cytometry. *Cytometry* 1998; 33: 97–105.
174. Herzenberg LA, Tung J, Moore WA, et al. Interpreting flow cytometry data: a guide for the perplexed. *Nat Immunol* 2006; 7: 681–685.
175. Irving J, Jesson J, Virgo P, et al. Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting. *Haematologica* 2009; 94: 870–874.
176. Jennings CD, Foon KA. Flow cytometry: recent advances in diagnosis and monitoring of leukemia. *Cancer Invest* 1997; 15: 384–399.
177. Johnson RL. Flow cytometry. From research to clinical laboratory applications. *Clin Lab Med* 1993; 13: 831–852.
178. Kappelmayer J, Gratama JW, Karászi E, et al. Flow cytometric detection of intracellular myeloperoxidase, CD3 and CD79a. Interaction between monoclonal antibody clones, fluorochromes and sample preparation protocols. *J Immunol Methods* 2000; 242: 53–65.
179. Kern W, Kohlmann A, Schoch C, et al. Comparison of mRNA abundance quantified by gene expression profiling and percentage of positive cells using immunophenotyping for diagnostic antigens in acute and chronic leukemias. *Cancer* 2006; 107: 2401–2407.
180. Koester SK, Bolton WE. Intracellular markers. *J Immunol Methods* 2000; 243: 99–106.
181. Kraan J, Gratama JW, Keeney M, et al. Setting up and calibration of a flow cytometer for multicolor immunophenotyping. *J Biol Regul Homeost Agents* 2003; 17: 223–233.
182. Lanza F, Latorraca A, Moretti S, et al. Comparative analysis of different permeabilization methods for the flow cytometry measurement of cytoplasmic myeloperoxidase and lysozyme in normal and leukemic cells. *Cytometry* 1997; 30:134–144.
183. Lemmers B, Arnoulet C, Fossat C, et al. Fine characterization of childhood and adult acute lymphoblastic leukemia (ALL) by a proB and preB surrogate light chain-specific mAb and a proposal for a new B cell ALL classification. *Leukemia* 2000; 14: 2103–2111.
184. Li W, Chen Z, Liu Z, et al. Application of CD45/SSC gating multiparameter flow cytometry in the classification of acute leukemia--an analysis of 139 cases. J. Tongji Med. Univ. *Tong Ji Yi Ke Xue Xue Bao* 2001; 21: 209–211.
185. Macey MG, McCarthy DA, Milne T, et al. Comparative study of five commercial reagents for preparing normal and leukaemic lymphocytes for immunophenotypic analysis by flow cytometry. *Cytometry* 1999; 38: 153–160.
186. Maynadié M, Campos L, Moskovtchenko P, et al. Heterogenous expression of CD15 in acute lymphoblastic leukemia: a study of ten anti-CD15 monoclonal antibodies in 158 patients. *Leuk Lymphoma* 1997; 25: 135–143.
187. Nakase K, Sartor M, Bradstock K. Detection of myeloperoxidase by flow cytometry in acute leukemia. *Cytometry* 1998; 34: 198–202.
188. Owens MA, Vall HG, Hurley AA, et al. Validation and quality control of immunophenotyping in clinical flow cytometry. *J Immunol Methods* 2000; 243: 33–50.
189. Parks DR, Roederer M, Moore WA. A new “Logicle” display method avoids deceptive effects of logarithmic scaling for low signals and compensated data. *Cytometry Part A* 2006; 69A: 541–551.
190. Raife TJ, Lager DJ, Kemp JD, et al. Expression of CD24 (BA-1) predicts monocytic lineage in acute myeloid leukemia. *Am J Clin Pathol* 1994; 101: 296–299.
191. Ratei R, Karawajew L, Lacombe F, et al. Discriminant function analysis as decision support system for the diagnosis of acute leukemia with a minimal four color screening panel and multiparameter flow cytometry immunophenotyping. *Leukemia* 2007; 21: 1204–1211.
192. Re F, Arpinati M, Testoni N, et al. Expression of CD86 in acute myelogenous leukemia is a marker of dendritic/monocytic lineage. *Exp Hematol* 2002; 30: 126–134.
193. Rego EM, Garcia AB, Carneiro JJ, et al. Immunophenotype of normal and leukemic bone marrow B-precursors in a Brazilian population. A comparative analysis by quantitative fluorescence cytometry. *Braz J Med Biol Res* 2001; 34: 183–194.
194. Riccioni R, Pelosi E, Riti V, et al. Immunophenotypic features of acute myeloid leukaemia patients exhibiting high FLT3 expression not associated with mutations. *Br J Haematol* 2011; 153: 33–42.
195. Riley RS, Massey D, Jackson-Cook C, et al. Immunophenotypic analysis of acute lymphocytic leukemia. *Hematol Oncol Clin N Am* 2002; 16: 245–299.
196. Rimsza LM, Larson RS, Winter SS, et al. Benign hematogone-rich lymphoid proliferations can be distinguished from B-lineage acute lymphoblastic leukemia by integration of morphology, immunophenotype, adhesion molecule expression, and architectural features. *Am J Clin Pathol* 2000; 114: 66–75.
197. Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Working Group on Flow Cytometry and Image Analysis. *Leukemia* 1996; 10: 877–895.
198. Ruiz-Argüelles A, Rivadeneyra-Espinoza L, Duque RE, et al. Report on the second Latin American consensus conference for flow cytometric immunophenotyping of hematological malignancies. *Cytometry B Clin Cytom* 2006; 70B: 39–44.
199. Sartor M, Bradstock K. Detection of intracellular lymphoid differentiation antigens by flow cytometry in acute lymphoblastic leukemia. *Cytometry* 1994; 18: 119–122.
200. Saxena R, Anand H. Flow cytometry in acute leukemia. *Indian J Hematol Blood Transfus* 2008; 24: 146–150.
201. Schwonzen M, Diehl V, Dellanna M, et al. Immunophenotyping of surface antigens in acute myeloid leukemia by flow cytometry after red blood cell lysis. *Leuk Res* 2007; 31: 113–116.
202. Seegmiller AC, Kroft SH, Karandikar NJ, et al. Characterization of immunophenotypic aberrancies in 200 cases of B acute lymphoblastic leukemia. *Am J Clin Pathol* 2009; 132: 940–949.
203. Sengar M, Rai AK, Saxena A, et al. Acute leukemia: Diagnosis improved by flow cytometry in addition to morphology. *Asia Pac J Clin Oncol* 2009; 5: 55–65.
204. Tiirikainen MI. Evaluation of red blood cell lysing solutions for the detection of intracellular antigens by flow cytometry. *Cytometry* 1995; 20: 341–348.
205. Tung JW, Parks DR, Moore WA, et al. New approaches to fluorescence compensation and visualization of FACS data. *Clin Immunol* 2004; 110: 277–283.
206. van Dongen JJM, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. *Leukemia* 2012; 26: 1908–1975.
207. Verwer BJ, Terstappen LW. Automatic lineage assignment of acute leukemias by flow cytometry. *Cytometry* 1993; 14: 862–875.
208. Wehner S, Soerensen J, Schwabe D, et al. 10-Parameter flow cytometry as a new tool to improve diagnosis and MRD follow-up of acute leukemias. *Klin Padiatr* 2009; 221: 393–395.
209. Keeney M, Gratama JW, Chin-Yee IH, et al. Isotype controls in the analysis of lymphocytes and CD34+ stem and progenitor cells by flow cytometry-time to let go! *Cytometry* 1998; 34: 280-283.
210. Orfao A, Ruiz-Arguelles A, Lacombe F, et al. Flow cytometry: its applications in hematology. *Haematologica* 1995; 80: 69-81.
211. Li W, Pizzolo J, Ahsan R, et al. Flow Cytometry in the diagnosis of acute promyelocytic leukemia (APL) – What we learn from outliers. *Lab Invest* 2013: 342A.
212. Mirkowska P, Hofmann A, Sedek L, et al. Leukemia surfaceome analysis reveals new disease-associated features. *Blood* 2013; 121: e149-159.
213. van den Ancker W, Westers TM, de Leeuw DC, et al. A threshold of 10% for myeloperoxidase by flow cytometry is valid to classify acute leukemia of ambiguous and myeloid origin. *Cytometry B Clin Cytom* 2013; 84: 114–118.
214. Verigou E, Kolliopoulou G, Smirni N, et al. Hesk ratio: A complementary tool for the diagnosis of myelodysplastic syndromes and a novel method for flow cytometry analysis. *Blood* 2012: 4946.
215. Zhou Y, Jorgensen JL, Wang SA, et al. Usefulness of CD11a and CD18 in flow cytometric immunophenotypic analysis for diagnosis of acute promyelocytic leukemia. *Am J Clin Pathol* 2012; 138: 744–750.
216. Morilla R, Moss K, Nikolova V, et al. The use of unfixed bone marrow trephines for multicolour flow cytometry. *Methods* 2018; 134-135: 80-86.
217. Park SI, Rogers BB. Monocytopenia as a diagnostic clue to pediatric B-lymphoblastic leukemia with rare circulating blasts. *Pediatr Dev Pathol* 2014; 17: 112–117.
218. Rajab A, Porwit A. Screening bone marrow samples for abnormal lymphoid populations and myelodysplasia-related features with one 10-color 14-antibody screening tube. *Cytometry B Clin Cytom* 2015; 88B: 253-260.
219. Sędek Ł, Bulsa J, Sonsala A, et al. The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: how different are they from their normal counterparts? *Cytometry B Clin Cytom* 2014; 86B: 329–339.
220. Al-Mawali A, Gillis D, Lewis I. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. *Am J Clin Pathol* 2009; 131: 16–26.
221. Bene MC, Bernier M, Casasnovas RO, Castoldi G, et al. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). *Blood* 1998; 92: 596–599.
222. Borowitz MJ, Bray R, Gascoyne R, et al. U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: data analysis and interpretation. *Cytometry* 1997; 30: 236–244.
223. Campana D, Behm FG. Immunophenotyping of leukemia. *J Immunol Methods* 2000; 243: 59–75.
224. Campana D. Minimal residual disease in acute lymphoblastic leukemia. *Hematology* 2010; 2010: 7–12.
225. Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. *Cytometry* 1999; 38: 139–152.
226. Chianese R, Brando B, Gratama JW, et al. Diagnostic and prognostic value of flow cytometric immunophenotyping in malignant hematological diseases. *J Biol Regul Homeost Agents* 2002; 16: 259–269.
227. Cohen PL, Hoyer JD, Kurtin PJ, et al. Acute myeloid leukemia with minimal differentiation. A multiple parameter study. *Am J Clin Pathol* 1998; 109: 32–38.
228. Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. *Blood* 2008; 111: 3941–3967.
229. Dunphy CH. Applications of flow cytometry and immunohistochemistry to diagnostic hematopathology. *Arch Pathol Lab Med 2004*; 128: 1004–1022.
230. McKenna RW. Multifaceted approach to the diagnosis and classification of acute leukemias. *Clin Chem* 2000; 46: 1252–1259.
231. Onciu M. Acute lymphoblastic leukemia. *Hematol Oncol Clin N Am* 2009; 23: 655–674.
232. Orfao A, Ciudad J, Gonzalez M, et al. Flow cytometry in the diagnosis of cancer. *Scand J Clin Lab Investig* 1995; 55 Suppl 221: 145–152.
233. Ossenkoppele GJ, van de Loosdrecht AA, Schuurhuis GJ. Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms. *Br J Haematol* 2011; 153: 421–436.
234. Paietta E. Expression of cell-surface antigens in acute promyelocytic leukaemia. *Best Pract Res Clin Haematol* 2003; 16: 369–385.
235. Plesa C, Chelghoum Y, Plesa A, et al. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience. *Cancer* 2008; 112: 572–580.
236. Raspadori D, Lauria F, Ventura MA, et al. Incidence and prognostic relevance of CD34 expression in acute myeloblastic leukemia: analysis of 141 cases. *Leuk Res* 1997; 21: 603–607.
237. Sun T. Immunophenotyping of hematologic neoplasms by combined flow cytometry and immunohistochemistry. *J Clin Ligand Assay* 2004; 27: 180-189.
238. Szczepański T, van der Velden VHJ, van Dongen JJM. Flow-cytometric immunophenotyping of normal and malignant lymphocytes. *Clin Chem Lab Med* 2006; 44: 775–796.
239. Wang JC, Beauregard P, Soamboonsrup P, et al. Monoclonal antibodies in the management of acute leukemia. *Am J Hematol* 1995; 50: 188–199.
240. Ward MS. The use of flow cytometry in the diagnosis and monitoring of malignant hematological disorders. *Pathology* 1999; 31: 382–392.
241. Weir EG, Borowitz MJ. Flow cytometry in the diagnosis of acute leukemia. *Semin Hematol* 2001; 38: 124–138.
242. Zuo Z, Polski JM, Kasyan A, et al. Acute erythroid leukemia. *Arch Pathol Lab Med* 2010; 134: 1261–1270.
243. Béné MC. Biphenotypic, bilineal, ambiguous or mixed lineage: strange leukemias! *Haematologica* 2009; 94: 891–893.
244. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). *Leukemia* 1995; 9: 1783–1786.
245. Gluzman DF, Sklyarenko LM, Zavelevich MP, et al. Leukemic blast cells and controversies in models of hematopoiesis. *Exp Oncol* 2015; 37: 2–4.
246. Hrušák O, Basso G, Ratei R, et al. Flow diagnostics essential code: a simple and brief format for the summary of leukemia phenotyping. *Cytometry B Clin Cytom* 2014; 86B: 288–291.
247. Riaz W, Zhang L, Horna P, et al. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy. *Cancer Control* 2014; 21: 279–289.
248. Shi Y, Wang E. Blastic plasmacytoid dendritic cell neoplasm: a clinicopathologic review. *Arch Pathol Lab Med* 2014; 138: 564–569.